Ignite Creation Date:
2024-05-06 @ 9:56 AM
Last Modification Date:
2024-10-26 @ 12:21 PM
Study NCT ID:
NCT03110445
Status:
WITHDRAWN
Last Update Posted:
2020-02-07
First Post:
2016-05-11
Brief Title:
CancerTestis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus
Sponsor:
University Hospital Basel Switzerland
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
Monocentric Open Label Phase I Immunotherapy Trial of Breast Cancer Patients With a Non-replicating Recombinant Vaccinia Virus Expressing CancerTestis Antigens and Cluster of Differentiation Antigen 80 CD80-CD40L Costimulatory Molecules
Status:
WITHDRAWN
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
not sufficiently staff available to perform trial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
rVV-740CTA
Brief Summary:
Monocentric open-label phase III trial aiming at evaluating in adjuvant setting safety primary outcome immunological and clinical efficacy secondary outcomes of a non replicating recombinant vaccinia virus expressing cancertestis antigen CTA derived epitopes and CD80 and CD40 ligand CD40L CD154 costimulatory molecules in patients with CTA expressing tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None